In vitro antifungal activity of anidulafungin;Actividad antifúngica in vitro de la anidulafungina

Revista Iberoamericana de Micologia

Volumn 25, Issue 2, 2008, Pages 83-91

  Quindós, Guillermo ^a   Eraso, Elena ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Anidulafungin; Antifungal agents; Aspergillus; Candida; In vitro activity; Moulds; Yeasts

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ASPERGILLUS; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA GUILLIERMONDII; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CRYPTOCOCCUS; DRUG SENSITIVITY; IN VITRO STUDY; INVASIVE CANDIDIASIS; MEDICAL LITERATURE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PNEUMOCYSTIS; REVIEW; SCIENTIFIC LITERATURE; ZYGOMYCETES;

ASPERGILLUS; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; FUNGI; ISSATCHENKIA ORIENTALIS; PICHIA GUILLIERMONDII; PNEUMOCYSTIS; ZYGOMYCETES;

ANTIFUNGAL AGENTS; ECHINOCANDINS; FUNGI; MICROBIAL SENSITIVITY TESTS;

EID: 44849121000     PISSN: 11301406     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1130-1406(08)70025-1     Document Type: Review

References (93)

1. Alexander BD, Schell WA, Miller JL, Long GD, Perfect JR. Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole. Transplantation 2005; 80: 868-871.
2. Almirante B, Rodriguez D, Cuenca-Estrella M, Almela M, Sanchez F, Ayats J, Alonso-Tarres C, Rodriguez-Tudela JL, Pahissa A. Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: case-control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2006; 44: 1681-1685.
3. Aperis G, Mylonakis E. Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations. Expert Opin Investig Drugs 2006; 15: 579-602.
4. Arevalo MP, Carrillo-Muñoz AJ, Salgado J, Cardenes D, Brio S, Quindós G, Espinel-Ingroff A. Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method. J Antimicrob Chemother 2003; 51: 163-166.
5. Barnes PD, Marr KA. Aspergillosis: spectrum of disease, diagnosis, and treatment. Infect Dis Clin North Am 2006; 20: 545-561.
6. Bartlett MS, Current WL, Goheen MP, Boylan CJ, Lee CH, Shaw MM, Queener SF, Smith JW. Semisynthetic echinocandins affect cell wall deposition of Pneumocystis carinii in vitro and in vivo. Antimicrob Agents Chemother 1996; 40: 1811-1816.
7. Bouza E, Munoz P. Invasive infections caused by Blastoschizomyces capitatus and Scedosporium spp. Clin Microbiol Infect 2004; 10 (Supl. 1): 76-85.
8. Bouza E, Munoz P, Guinea J. Mucormycosis: an emerging disease? Clin Microbiol Infect 2006; 12 (Supl. 7): 7-23.
9. Brummer E, Chauhan SD, Stevens DA. Collaboration of human phagocytes with LY 303366 for antifungal activity against Aspergillus fumigatus. J Antimicrob Chemother 1999; 43: 491-496.
10. a ed. Bilbao, Revista Iberoamericana de Micología-Asociación Española de Micología, 2007: 15a-1-15a-17.
11. Cappelletty D, Eiselstein-McKitrick K. The echinocandins. Pharmacotherapy 2007; 27: 369-388.
12. Carrillo-Muñoz AJ, Quindós G, del Valle O, Santos P, Giusiano G, Ezkurra PA, Estivill MD, Casals JB. Activity of caspofungin and voriconazole against clinical isolates of Candida and other medically important yeasts by the CLSI M-44A disk diffusion method with Neo-Sensitabs tablets. Chemotherapy 2008; 54: 38-42.
13. Carrillo-Muñoz AJ, Quindós G, López-Ribot JL. Current developments in antifungal agents. Current Medicinal Chemistry - Anti-Infective Agents 2004; 3: 297-323.
14. Chavez M, Bernal S, Valverde A, Gutiérrez MJ, Quindós G, Mazuelos EM. In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients. J Antimicrob Chemother 1999; 44: 697-700.
15. Cota J, Carden M, Graybill JR, Najvar LK, Burgess DS, Wiederhold NP. In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility. Antimicrob Agents Chemother 2006; 50: 3926-3928.
16. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Buitrago MJ, Monzon A, Rodriguez-Tudela JL. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother 2006; 50: 917-921.
17. Cuenca-Estrella M, Mellado E, Díaz-Guerra TM, Monzon A, Rodriguez-Tudela JL. Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B. J Antimicrob Chemother 2000; 46: 475-477.
18. Del Palacio A, Pontón J, Guarro J, Quindós G. Guía de bolsillo de las zigomicosis invasoras. Bilbao, Revista Iberoamericana de Micología, 2008.
19. Di Bonaventura G, Pompilio A, Picciani C, Allezzi M, D'Antonio D, Piccolomini R. Biofilm formation by the emerging fungal pathogen Trichosporon asahii: development, architecture, and antifungal resistance. Antimicrob Agents Chemother 2006; 50: 3269-3276.
20. Douglas CM. Fungal beta(1,3)-D-glucan synthesis. Med Mycol 2001; 39 (Supl. 1): 55-66.
21. Dowell JA, Stogniew M, Krause D, Henkel T, Damle B. Lack of pharmacokinetic interaction between anidulafungin and tacrolimus. J Clin Pharmacol 2007; 47: 305-314.
22. Eraso E, Quindós G, Albaina O, Marcos C, Varona A, Hernández-Almaraz JL, Alkorta M, Carrillo-Muñoz AJ, Pontón J. Activity of anidulafungin against Spanish blood isolates of Candida. J Chemother 2007; 19 (Supl. 3): 43.
23. Espinel-Ingroff A. Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998; 36: 2950-2956.
24. Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev Iberoam Micol 2003; 20: 121-136.
25. Espinel-Ingroff A, Fothergill A, Ghannoum M, Manavathu E, Ostrosky-Zeichner L, Pfaller MA, Rinaldi MG, Schell W, Walsh TJ. Quality control and reference guidelines for CLSI broth microdilution method (M38-A document) for susceptibility testing of anidulafungin against molds. J Clin Microbiol 2007; 45: 2180-2182.
26. Fukuda T, Boeckh M, Guthrie KA, Mattson DK, Owens S, Wald A, Sandmaier BM, Corey L, Storb RF, Marr KA. Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center. Biol Blood Marrow Transplant 2004; 10: 494-503.
27. Gacser A, Schafer W, Nosanchuk JS, Salomon S, Nosanchuk JD. Virulence of Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis in reconstituted human tissue models. Fungal Genet Biol 2007; 44: 1336-1341.
28. Gutiérrez J, Morales P, González MA, Quindós G. Candida dubliniensis, a new fungal pathogen. J Basic Microbiol 2002; 42: 207-227.
29. Hakki M, Staab JF, Marr KA. Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob Agents Chemother 2006; 50: 2522-2524.
30. Jacobsen MD, Whyte JA, Odds FC. Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. Antimicrob Agents Chemother 2007; 51: 1882-1884.
31. Kahn JN, Garcia-Effron G, Hsu MJ, Park S, Marr KA, Perlin DS. Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase. Antimicrob Agents Chemother 2007; 51: 1876-1878.
32. Karlowsky JA, Hoban DJ, Zhanel GG, Goldstein BP. In vitro interactions of anidulafungin with azole antifungals, amphotericin B and 5-fluorocytosine against Candida species. Int J Antimicrob Agents 2006; 27: 174-177.
33. Kim R, Khachikian D, Reboli AC. A comparative evaluation of properties and clinical efficacy of the echinocandins. Expert Opin Pharmacother 2007; 8: 1479-1492.
34. Kontoyiannis DP, Lionakis MS, Lewis RE, Chamilos G, Healy M, Perego C, Safdar A, Kantarjian H, Champlin R, Walsh TJ, Raad II. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus- active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005; 191: 1350-1360.
35. Krause DS, Simjee AE, van Rensburg C, Viljoen J, Walsh TJ, Goldstein BP, Wible M, Henkel T. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 2004; 39: 770-775.
36. Krogh-Madsen M, Arendrup MC, Heslet L, Knudsen JD. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin Infect Dis 2006; 42: 938-944.
37. Kuse ER, Chetchotisakd P, da Cunha CA, Ruhnke M, Barrios C, Raghunadharao D, Sekhon JS, Freire A, Ramasubramanian V, Demeyer I, Nucci M, Leelarasamee A, Jacobs F, Decruyenaere J, Pittet D, Ullmann AJ, Ostrosky-Zeichner L, Lortholary O, Koblinger S, Diekmann-Berndt H, Cornely OA. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007; 369: 1519-1527.
38. Lass-Florl C, Griff K, Mayr A, Petzer A, Gastl G, Bonatti H, Freund M, Kropshofer G, Dierich MP, Nachbaur D. Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience. Br J Haematol 2005; 131: 201-207.
39. Laverdiere M, Labbe AC, Restieri C, Rotstein C, Heyland D, Madger S, Stewart T. Susceptibility patterns of Candida species recovered from Canadian intensive care units. J Crit Care 2007; 22: 245-250.
40. Laverdiere M, Lalonde RG, Baril JG, Sheppard DC, Park S, Perlin DS. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J Antimicrob Chemother 2006; 57: 705-708.
41. Marco F, Pfaller MA, Messer SA, Jones RN. Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp. Diagn Microbiol Infect Dis 1998; 32: 33-37.
42. Marine M, Serena C, Pastor J, Quindos G, Carrillo AJ, Guarro J. In vitro activity of micafungin combined with itraconazole against Candida spp. Int J Antimicrob Agents 2007; 30: 463-465.
43. Messer SA, Kirby JT, Sader HS, Fritsche TR, Jones RN. Initial results from a longitudinal international surveillance programme for anidulafungin (2003). J Antimicrob Chemother 2004; 54: 1051-1056.
44. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, Lupinacci R, Sable C, Kartsonis N, Perfect J. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-2029.
45. Moudgal V, Little T, Boikov D, Vazquez JA. Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother 2005; 49: 767-769.
46. Mun̄oz P, Sanchez-Somolinos M, Alcala L, Rodriguez-Creixems M, Pelaez T, Bouza E. Candida krusei fungaemia: antifungal susceptibility and clinical presentation of an uncommon entity during 15 years in a single general hospital. J Antimicrob Chemother 2005; 55: 188-193.
47. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard. NCCLS document M38-A. Wayne, PA: National Committee for Clinical Laboratory Standards, 2002.
48. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard. 2nd Ed. NCCLS document M27-A2. Wayne, PA: National Committee for Clinical Laboratory Standards, 2002.
49. Odabasi Z, Paetznick VL, Rodriguez JR, Chen E, Ostrosky-Zeichner L. In vitro activity of anidulafungin against selected clinically important mold isolates. Antimicrob Agents Chemother 2004; 48: 1912-1915.
50. Odds FC, Hanson MF, Davidson AD, Jacobsen MD, Wright P, Whyte JA, Gow NA, Jones BL. One year prospective survey of Candida bloodstream infections in Scotland. J Med Microbiol 2007; 56: 1066-1075.
51. Ortoneda M, Capilla J, Pastor FJ, Pujol I, Yustes C, Serena C, Guarro J. In vitro interactions of approved and novel drugs against Paecilomyces spp. Antimicrob Agents Chemother 2004; 48: 2727-2729.
52. Ostrosky-Zeichner L, Rex JH, Pappas PG, Hamill RJ, Larsen RA, Horowitz HW, Powderly WG, Hyslop N, Kauffman CA, Cleary J, Mangino JE, Lee J. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003; 47: 3149-3154.
53. Passos XS, Costa CR, Araujo CR, Nascimento ES, Souza LK, Fernandes OF, Sales WS, Silva MR. Species distribution and antifungal susceptibility patterns of Candida spp. bloodstream isolates from a Brazilian tertiary care hospital. Mycopathologia 2007; 163: 145-151.
54. Pelletier R, Alarie I, Lagace R, Walsh TJ. Emergence of disseminated candidiasis caused by Candida krusei during treatment with caspofungin: case report and review of literature. Med Mycol 2005; 43: 559-564.
55. Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Diekema DJ. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: Six years of global surveillance. J Clin Microbiol 2008; 46: 150-156.
56. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J Clin Microbiol 2005; 43: 5425-5427.
57. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20: 133-163.
58. Pfaller MA, Diekema DJ, Boyken L, Messer SA, Tendolkar S, Hollis RJ, Goldstein BP. Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis. Antimicrob Agents Chemother 2005; 49: 4795-4797.
59. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Nagy E, Dobiasova S, Rinaldi M, Barton R, Veselov A. Candida krusei, a multidrug-resistant opportunistic fungal pathogen: Geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program, 2001-2005. J Clin Microbiol 2008; 46: 515-521.
60. Pfaller MA, Diekema DJ, Mendez M, Kibbler C, Erzsebet P, Chang SC, Gibbs DL, Newell VA. Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program. J Clin Microbiol 2006; 44: 3551-3556.
61. Pfaller MA, Marco F, Messer SA, Jones RN. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn Microbiol Infect Dis 1998; 30: 251-255.
62. Pfaller MA, Messer SA, Boyken L, Tendolkar S, Hollis RJ, Diekema DJ. Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002. J Clin Microbiol 2004; 42: 3142-3146.
63. Philip A, Odabasi Z, Rodriguez J, Paetznick VL, Chen E, Rex JH, Ostrosky-Zeichner L. In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp. Antimicrob Agents Chemother 2005; 49: 3572-3574.
64. Prabhu RM, Orenstein R. Failure of caspofungin to treat brain abscesses secondary to Candida albicans prosthetic valve endocarditis. Clin Infect Dis 2004; 39: 1253-1254.
65. Quindós G. New microbiological techniques for the diagnosis of invasive mycoses caused by filamentous fungi. Clin Microbiol Infect 2006; 12 (Supl. 7): 40-52.
66. Quindós G, Alkorta M, Rodríguez-Andrés C, Ullibarri B, Hernández-Almaraz JL. Epidemiological trends of candidemia in the tertiary-care hospital of Cruces, Barakaldo (Spain). Paris, The 16th Congress of the Internacional Society for Human and Animal Mycology, 2006.
67. Quindós G, Carrillo-Muñoz AJ, Arévalo MP, Salgado J, Alonso-Vargas R, Rodrigo JM, Ruesga MT, Valverde A, Pemán J, Cantón E, Martin-Mazuelos E, Pontón J. In vitro susceptibility of Candida dubliniensis to current and new antifungal agents. Chemotherapy 2000; 46: 395-401.
68. Quindós G, Carrillo-Muñoz AJ, Eraso E, Cantón E, Pemán J. Actividad antifúngica in vitro de voriconazol: Nuevos datos después de los primeros años de experiencia clínica. Rev Iberoam Micol 2007; 24: 198-208.
69. Quindós G, Carrillo-Muñoz AJ, Ruesga MT, Alonso-Vargas R, Miranda Y, Tur-Tur C, Rubio M, Wallace TL, Cossum PA, Martin-Mazuelos E, Cisterna R, Pontón J. In vitro activity of a new liposomal nystatin formulation against opportunistic fungal pathogens. Eur J Clin Microbiol Infect Dis 2000; 19: 645-648.
70. Quindoś G, Sánchez-Vargas LO, Villar-Vidal M, Eraso E, Alkorta M, Hernández-Almaraz JL. Activities of fluconazole and voriconazole against bloodstream isolates of Candida glabrata and Candida krusei: a 14-year study in a Spanish tertiary medical centre. Int J Antimicrob Agents 2008; 31: 266-271.
71. Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, Betts R, Wible M, Goldstein BP, Schranz J, Krause DS, Walsh TJ. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356: 2472-2482.
72. Rodrigues AG, Araujo R, Pina-Vaz C. Interaction of local anaesthetics with other antifungal agents against pathogenic Aspergillus. Int J Antimicrob Agents 2006; 27: 339-343.
73. Rodriguez D, Almirante B, Park BJ, Cuenca-Estrella M, Planes AM, Sanchez F, Gene A, Xercavins M, Fontanels D, Rodriguez-Tudela JL, Warnock DW, Pahissa A. Candidemia in neonatal intensive care units: Barcelona, Spain. Pediatr Infect Dis J 2006; 25: 224-229.
74. Roling EE, Klepser ME, Wasson A, Lewis RE, Ernst EJ, Pfaller MA. Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Cryptococcus neoformans via time-kill methods. Diagn Microbiol Infect Dis 2002; 43: 13-17.
75. San Miguel LG, Cobo J, Otheo E, Martos I, Muriel A, Fortun J, Moreno S. Candidemia in pediatric patients with congenital heart disease. Diagn Microbiol Infect Dis 2006; 55: 203-207.
76. San Miguel LG, Cobo J, Otheo E, Sanchez-Sousa A, Abraira V, Moreno S. Secular trends of candidemia in a large tertiary-care hospital from 1988 to 2000: emergence of Candida parapsilosis. Infect Control Hosp Epidemiol 2005; 26: 548-552.
77. Sandven P. Epidemiology of candidemia. Rev Iberoam Micol 2000; 17: 73-81.
78. Sandven P, Bevanger L, Digranes A, Haukland HH, Mannsaker T, Gaustad P. Candidemia in Norway (1991 to 2003): results from a nationwide study. J Clin Microbiol 2006; 44: 1977-1981.
79. Sanz Alonso MA, Jarque Ramos I, Salavert Llatí M, Pemán J. Epidemiology of invasive fungal infections due to Aspergillus spp. and Zygomycetes. Clin Microbiol Infect 2006; 12: 2-6.
80. Serena C, Fernandez-Torres B, Pastor FJ, Trilles L, Lazera MS, Nolard N, Guarro J. In vitro interactions of micafungin with other antifungal drugs against clinical isolates of four species of Cryptococcus. Antimicrob Agents Chemother 2005; 49: 2994-2996.
81. Serena C, Marine M, Pastor FJ, Nolard N, Guarro J. In vitro interaction of micafungin with conventional and new antifungals against clinical isolates of Trichosporon, Sporobolomyces and Rhodotorula. J Antimicrob Chemother 2005; 55: 1020-1023.
82. Serena C, Marine M, Quindós G, Carrillo AJ, Cano JF, Pastor FJ, Guarro J. In vitro interactions of micafungin with amphotericin B against clinical isolates of Candida spp. Antimicrob Agents Chemother 2008; en prensa.
83. Serrano MC, Valverde-Conde A, Chavez MM, Bernal S, Clara RM, Peman J, Ramirez M, Martin-Mazuelos E. In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against Aspergillus spp. Diagn Microbiol Infect Dis 2003; 45: 131-135.
84. Steinbach WJ, Benjamin DKJr, Kontoyiannis DP, Perfect JR, Lutsar I, Marr KA, Lionakis MS, Torres HA, Jafri H, Walsh TJ. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis 2004; 39: 192-198.
85. Tavanti A, Davidson AD, Gow NA, Maiden MC, Odds FC. Candida orthopsilosis and Candida metapsilosis spp. nov. to replace Candida parapsilosis groups II and III. J Clin Microbiol 2005; 43: 284-292.
86. Tortorano AM, Kibbler C, Peman J, Bernhardt H, Klingspor L, Grillot R. Candidaemia in Europe: epidemiology and resistance. Int J Antimicrob Agents 2006; 27: 359-366.
87. Valentin A, Cantón E, Pemán J, Quindós G. Actividad in vitro de la anfotericina B y la anidulafungina sobre biopeliculas de Candida albicans y Candida tropicalis. Rev Iberoam Micol 2007; 24: 272-277.
88. Vazquez JA. Anidulafungin: a new echinocandin with a novel profile. Clin Ther 2005; 27: 657-673.
89. Vazquez JA, Sobel JD. Anidulafungin: a novel echinocandin. Clin Infect Dis 2006; 43: 215-222.
90. Villar-Vidal M, Quindós G, Eraso E, Delgado-Naranjo J, Rodríguez-Andrés C, Pontón J. In vitro activity of anidulafungin against Candida albicans and Candida dubliniensis biofilms developed on polystyrene. J Chemother 2007; 19 (Supl. 3): 43.
91. Viudes A, Pemán J, Cantón E, Ubeda P, Lopez-Ribot JL, Gobernado M. Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death. Eur J Clin Microbiol Infect Dis 2002; 21: 767-774.
92. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-360.
93. Zhanel GG, Karlowsky JA, Harding GA, Balko TV, Zelenitsky SA, Friesen M, Kabani A, Turik M, Hoban DJ. In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species. Antimicrob Agents Chemother 1997; 41: 863-865.